Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Biochem J ; 392(Pt 3): 675-83, 2005 Dec 15.
Article in English | MEDLINE | ID: mdl-16086671

ABSTRACT

Triosephosphate isomerase (TPI) deficiency is a unique glycolytic enzymopathy coupled with neurodegeneration. Two Hungarian compound heterozygote brothers inherited the same TPI mutations (F240L and E145Stop), but only the younger one suffers from neurodegeneration. In the present study, we determined the kinetic parameters of key glycolytic enzymes including the mutant TPI for rational modelling of erythrocyte glycolysis. We found that a low TPI activity in the mutant cells (lower than predicted from the protein level and specific activity of the purified recombinant enzyme) is coupled with an increase in the activities of glycolytic kinases. The modelling rendered it possible to establish the steady-state flux of the glycolysis and metabolite concentrations, which was not possible experimentally due to the inactivation of the mutant TPI and other enzymes during the pre-steady state. Our results showed that the flux was 2.5-fold higher and the concentration of DHAP (dihydroxyacetone phosphate) and fructose 1,6-bisphosphate increased 40- and 5-fold respectively in the erythrocytes of the patient compared with the control. Although the rapid equilibration of triosephosphates is not achieved, the energy state of the cells is not 'sick' due to the activation of key regulatory enzymes. In lymphocytes of the two brothers, the TPI activity was also lower (20%) than that of controls; however, the remaining activity was high enough to maintain the rapid equilibration of triosephosphates; consequently, no accumulation of DHAP occurs, as judged by our experimental and computational data. Interestingly, we found significant differences in the mRNA levels of the brothers for TPI and some other, apparently unrelated, proteins. One of them is the prolyl oligopeptidase, the activity decrease of which has been reported in well-characterized neurodegenerative diseases. We found that the peptidase activity of the affected brother was reduced by 30% compared with that of his neurologically intact brother.


Subject(s)
Gene Expression Regulation, Enzymologic , Mutation/genetics , RNA, Messenger/genetics , Triose-Phosphate Isomerase/deficiency , Triose-Phosphate Isomerase/metabolism , Alleles , Catalysis , Erythrocytes/enzymology , Female , Gene Expression Profiling , Gene Expression Regulation, Enzymologic/genetics , Glycolysis , Humans , Hungary , Male , Oligonucleotide Array Sequence Analysis , Pedigree , RNA, Messenger/metabolism , Triose-Phosphate Isomerase/genetics
2.
Mol Cell Biochem ; 256-257(1-2): 83-93, 2004.
Article in English | MEDLINE | ID: mdl-14977172

ABSTRACT

Research in the last 10 years has revealed that the development of neurodegeneration is a multistep process during which one or few specific mutant protein species of altered conformation initiate aberrant protein-protein interactions resulting in aggregates forming plaques. This review focuses on the heteroassociations of the mutant proteins with subcellular structures, such as cytoskeleton, cell membranes or with glycolytic enzymes, which may be crucial in the initiation of neurodegeneration such as in Huntington's disease or Alzheimer's disease. Triosephosphate isomerase enzymopathy is a unique glycolytic enzyme deficiency coupled with neurodegeneration. We present data on the mutation induced misfolding process, which likely plays a crucial role in the enhanced associations of the enzyme with the truncated fragment of the isomerase, with the red cell membrane or with the microtubular network. On the basis of our recent clinical and experimental results obtained with two compound heterozygote Hungarian brothers it became obvious that the mutations alone are not sufficient to explain the development of the neurological sympthomes. This underscores the fact that the mutations alone are not enough for the development of the clinical phenotype of a disease.


Subject(s)
Brain/ultrastructure , Central Nervous System/pathology , Mutation , Proteins/metabolism , Animals , Brain/metabolism , Central Nervous System/metabolism , Glycolysis , Humans , Microtubules/metabolism , Protein Binding
3.
Mov Disord ; 19(1): 107-9, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14743370

ABSTRACT

A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase-B platelet activity was low in this patient.


Subject(s)
Anemia, Hemolytic, Congenital/genetics , Antiparkinson Agents/adverse effects , Basal Ganglia Diseases/genetics , Dyskinesia, Drug-Induced/etiology , Dystonia Musculorum Deformans/genetics , Glyceraldehyde-3-Phosphate Dehydrogenases/deficiency , Monoamine Oxidase Inhibitors/adverse effects , Neuroprotective Agents/adverse effects , Psychoses, Substance-Induced/etiology , Selegiline/adverse effects , Adolescent , Adult , Anemia, Hemolytic, Congenital/enzymology , Antiparkinson Agents/therapeutic use , Baclofen/adverse effects , Baclofen/therapeutic use , Basal Ganglia/drug effects , Basal Ganglia Diseases/drug therapy , Basal Ganglia Diseases/enzymology , Blood Platelets/enzymology , Drug Therapy, Combination , Dyskinesia, Drug-Induced/diagnosis , Dystonia Musculorum Deformans/drug therapy , Dystonia Musculorum Deformans/enzymology , Female , Genetic Carrier Screening , Genotype , Glyceraldehyde-3-Phosphate Dehydrogenases/genetics , Humans , Huntingtin Protein , Long-Term Care , Male , Middle Aged , Monoamine Oxidase/blood , Monoamine Oxidase/genetics , Monoamine Oxidase Inhibitors/therapeutic use , Nerve Tissue Proteins/genetics , Neurologic Examination/drug effects , Neuroprotective Agents/therapeutic use , Nuclear Proteins/genetics , Polymerase Chain Reaction , Proteins/genetics , Psychoses, Substance-Induced/diagnosis , Reference Values , Selegiline/therapeutic use , Trinucleotide Repeats
4.
Biochim Biophys Acta ; 1639(2): 121-32, 2003 Oct 15.
Article in English | MEDLINE | ID: mdl-14559119

ABSTRACT

Triosephosphate isomerase deficiency is associated with the accumulation of dihydroxyacetonephosphate (DHAP) to abnormally high levels, congenital haemolytic anaemia and a clinical syndrome of progressive neuromuscular degeneration leading to infant mortality. DHAP degrades spontaneously to methylglyoxal (MG)--a potent precursor of advanced glycation endproducts (AGEs). MG is detoxified to D-lactate intracellularly by the glyoxalase system. We investigated the changes in MG metabolism and markers of protein glycation, oxidation and nitrosation in a Hungarian family with two germline identical brothers, compound heterozygotes for triosephosphate isomerase deficiency, one with clinical manifestations of chronic neurodegeneration and the other neurologically intact. The concentration of MG and activity of glyoxalase I in red blood cells (RBCs) were increased, and the concentrations of D-lactate in blood plasma and D-lactate urinary excretion were also increased markedly in the propositus. There were concomitant increases in MG-derived AGEs and the oxidative marker dityrosine in hemoglobin. Smaller and nonsignificant increases were found in the neurologically unaffected brother and parents. There was a marked increase (15-fold) in urinary excretion of the nitrosative stress marker 3-nitrotyrosine in the propositus. The increased derangement of MG metabolism and associated glycation, oxidative and nitrosative stress in the propositus may be linked to neurodegenerative process in triosephosphate isomerase deficiency.


Subject(s)
Proteins/metabolism , Pyruvaldehyde/metabolism , Triose-Phosphate Isomerase/deficiency , Erythrocytes/enzymology , Glycosylation , Humans , Lactoylglutathione Lyase/metabolism , Nitrates/metabolism , Nitrosation , Oxidation-Reduction , Thiolester Hydrolases/metabolism , Triose-Phosphate Isomerase/metabolism
5.
Biochem Soc Trans ; 30(2): 30-8, 2002 04.
Article in English | MEDLINE | ID: mdl-12023819

ABSTRACT

A number of neurodegenerative diseases are mediated by mutation-induced protein misfolding. The resulting genetic defects, however, are expressed in varying phenotypes. Of the several well-established glycolytic enzyme deficiencies, triosephosphate isomerase (TPI) deficiency is the only one in which haemolytic anaemia is coupled with progressive, severe neurological disorder. In a Hungarian family with severe decrease in TPI activity, two germ line-identical but phenotypically differing compound heterozygote brothers inherited two independent (Phe(240)-->Leu and Glu(145)-->stop codon) mutations. We have demonstrated recently [Orosz, Oláh, Alvarez, Keserü, Szabó, Wágner, Kovári, Horányi, Baróti, Martial, Hollán and Ovádi (2001) Blood 98, 3106-3112] that the mutations of TPI explain in themselves neither the severe decrease in the enzyme activity characteristic of TPI deficiency nor the enhanced ability of the mutant enzyme from haemolysate of the propositus to associate with subcellular particles. Here we present kinetic (flux analysis), thermodynamic (microcalorimetry and fluores cence spectroscopy), structural (in silico) and ultrastructural (immunoelectron microscopy) data for characterization of mutant isomerase structures and for the TPI-related metabolic processes in normal and deficient cells. The relationships between mutation-induced TPI misfolding and formation of aberrant protein aggregates are discussed.


Subject(s)
Heredodegenerative Disorders, Nervous System/enzymology , Triose-Phosphate Isomerase/deficiency , Enzyme Stability , Glycolysis , Heredodegenerative Disorders, Nervous System/genetics , Humans , Kinetics , Male , Microtubules/enzymology , Microtubules/ultrastructure , Models, Molecular , Mutation , Pentose Phosphate Pathway , Protein Folding , Triose-Phosphate Isomerase/chemistry , Triose-Phosphate Isomerase/genetics , Triose-Phosphate Isomerase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...